Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Yifeng Pharmacy Chain Co., Ltd.
  6. Summary
    603939   CNE100001TS5

YIFENG PHARMACY CHAIN CO., LTD.

(603939)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Shanghai Stock Exchange
10/18/2021 10/19/2021 10/20/2021 10/21/2021 10/22/2021 Date
51.28 51.67 50.82 49.94 49.36 Last
2811237 2562799 1673647 3098943 2778229 Volume
-2.10% +0.76% -1.65% -1.73% -1.16% Change
Estimated financial data (e)
Sales 2021 16 151 M 2 531 M 2 531 M
Net income 2021 978 M 153 M 153 M
Net cash position 2021 1 078 M 169 M 169 M
P/E ratio 2021 36,2x
Yield 2021 0,59%
Sales 2022 20 403 M 3 197 M 3 197 M
Net income 2022 1 237 M 194 M 194 M
Net cash position 2022 1 967 M 308 M 308 M
P/E ratio 2022 28,6x
Yield 2022 0,76%
Capitalization 35 478 M 5 557 M 5 559 M
EV / Sales 2021 2,13x
EV / Sales 2022 1,64x
Nbr of Employees -
Free-Float 43,0%
More Financials
Company
Yifeng Pharmacy Chain Co., Ltd. is a China-based company principally engaged in the chain retailing of pharmaceuticals, health products, medical equipment and health-related household convenience products. The Company mainly operates through retailing segment. The Company operates more than 1, 000 direct pharmaceutical chain stores mainly in six provinces (or municipalities), including Hunan, Hubei, Shanghai,... 
Sector
Drug Retailers
Calendar
10/30Earnings Release
More about the company
Ratings of Yifeng Pharmacy Chain Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
D+
More Ratings
All news about YIFENG PHARMACY CHAIN CO., LTD.
08/26Yifeng Pharmacy Chain Co., Ltd. Reports Earnings Results for the Half Year Ended June 3..
CI
08/26Shanghai Yifeng Pharmacy Chain Co., Ltd. announced that it expects to receive CNY 90 mi..
CI
08/26Jiangsu Yifeng Pharmacy Chain Co., Ltd. announced that it expects to receive CNY 130 mi..
CI
08/26Ningbo Meishan Free Trade Zone Jikang Enterprise Management Partnership Enterprise (LP ..
CI
08/26Jiangxi Yifeng Pharmacy Chain Co., Ltd. announced that it expects to receive CNY 45 mil..
CI
08/26Jiangxi Yifeng Pharmaceutical Co., Ltd. announced that it expects to receive CNY 50 mil..
CI
08/26Shanghai Yifeng Pharmacy Co., Ltd announced that it expects to receive CNY 90 million i..
CI
04/29Yifeng Pharmacy Chain Co., Ltd. Reports Earnings Results for the First Quarter Ended Ma..
CI
04/27Yifeng Pharmacy Chain Co., Ltd. Reports Earnings Results for the Full Year Ended Decemb..
CI
2020Yifeng Pharmacy Chain Co., Ltd. Reports Earnings Results for the Nine Months Ended Sept..
CI
2020YIFENG PHARMACY CHAIN CO., LTD.(XSSC : 603939) added to FTSE All-World Index
CI
2020Yifeng Pharmacy Chain Co., Ltd. Reports Earnings Results for the Half Year Ended June 3..
CI
2020Yifeng Pharmacy Chain Co., Ltd. Announces Implementation Rights and Interests Distribut..
CI
2020Yifeng Pharmacy Chain Co., Ltd. Reports Earnings Results for the First Quarter Ended Ma..
CI
2020Yifeng Pharmacy Chain Co., Ltd. Reports Earnings Results for the Full Year Ended Decemb..
CI
More news
News in other languages on YIFENG PHARMACY CHAIN CO., LTD.

- No features available -

More news
Chart YIFENG PHARMACY CHAIN CO., LTD.
Duration : Period :
Yifeng Pharmacy Chain Co., Ltd. Technical Analysis Chart | 603939 | CNE100001TS5 | MarketScreener
Technical analysis trends YIFENG PHARMACY CHAIN CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 49,36 CNY
Average target price 74,71 CNY
Spread / Average Target 51,4%
EPS Revisions
Managers and Directors
Yi Gao Chairman & Chief Executive Officer
Jian Qin Deng Chief Financial Officer
Bin Chen Chairman-Supervisory Board
En Bo Zhang Member-Supervisory Board
Lan Guang Yi Independent Director
Sector and Competitors